HIV Infection: An Update on Antiretroviral Therapy
Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for
the issue, return to this Introduction page and click the "Take the Test" button. The Introduction
page will remain open after you open this issue.
You may need to re-size or close the issue in order
to see the Introduction page.
Twenty five years after the first case of AIDS was reported, the HIV epidemic remains at global proportions. The number of new HIV infections in the U.S. appears to have stabilized at about 55, 000 cases per year. Although this is a big increase over previous estimates, it results from improved reporting rather than an actual increase in new cases. A “cure” for HIV or an effective vaccine is unlikely to be introduced in the next few decades. Vaccine trials have been stopped due to higher rates of HIV infection among those vaccinated.
There are currently 23 approved anti-HIV agents among 6 classes. The newer drugs may improve adherence because of improved tolerability. New agents also allow most patients who have failed several drug regimens to achieve viral suppression similar to that of patients who are on their first anti-HIV drug regimen.
This issue reviews the 6 classes of anti-HIV drugs and the current recommendations for first-line treatment of HIV infection. Recently discovered life-threatening adverse effects of individual agents and long-term HAART are discussed. Easy-to-use tables provide detailed information on appropriate doses, administration strategies, side effects, and key drug interactions to help you effectively participate in drug therapy management. In the Rx Patient Connection, you’ll find the answers to commonly asked questions about HIV medications, including why “drug holidays” are no longer considered a good idea.
Publication Date: 11/01/2008
Expiration Date: 11/01/2011
CE Credit: 2.5 (0.25 CEU)
Type of Activity: Knowledge-based
This program was developed by The Rx Consultant and published by Continuing Education Network, Inc.
The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and
is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased,
balanced information to health care practitioners.
Programs developed by The Rx Consultant are written by health care providers with expertise in the topic
area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure
that every program presents information that is current, accurate, relevant to "real world" health care
providers, and written in an easy reading, "plain English" style.
Betty J. Dong, Professor of Clinical Pharmacy, University of California, San Francisco and HIV Pharmacist Specialist for the National HIV Clinicians’ Consultation Center, the Family HIV Clinic at San Francisco General Hospital, the Correctional Medicine Consultation Center, and the International Training and Education Centers for HIV (ITECH).
Disclosure of any financial or personal relationship between the author(s) and any commercial interest
producing, marketing, reselling, or distributing a product that appears in this issue is a requirement of publication in The Rx Consultant.Dr. Dong reports she is an investigator on a study funded by Merck.
This accredited program is targeted to pharmacists and nurses.
Goals & Objectives
At the conclusion of this program, participants will be able to:
- Identify the preferred antiretroviral regimens for treatment of antiretroviral naïve persons.
- Discuss the mechanism, adverse effects, drug interactions, and role in therapy of the newest FDA approved ARVs.
- Counsel patients about the proper dosage, administration, side effects, and drug interactions associated with the newest ARVs.
- Identify the major complications associated with HAAR and stopping HAART.
The Rx Consultant is a publication of Continuing Education Network, Inc.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education as a
provider of continuing pharmacy education.
Continuing Education Network is approved by the California Board of Registered Nursing, Provider Number CEP 13118. Programs approved by CA BRN are accepted by most State Boards of Nursing.
ACPE Universal Activity Number: 428-0000-08-010-H02-P
Exam & Credit Statement Procedures
Upon successful completion of this program and the post test (70%), 2.5 hours of continuing education credit will be awarded. To receive credit and your exam score, please complete the exam questions and
Editorial and Review Board
Chief Editor and CE Administrator
Terry M. Baker, PharmD
Tracy Farnen, PharmD
James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Coordinator
Associate Clinical Professor
School of Pharmacy
University of California San Francisco
San Francisco, CA
Richard Ron Finley, B.S. Pharm.,R.Ph.
Clinical Pharmacist (volunteer faculty)
University of California, San Francisco (UCSF) Memory and Aging Center
Lecturer (Emeritus) UCSF, Department of Clinical Pharmacy
Health Sciences Clinical Professor, UCSF School of Pharmacy
San Francisco, CA
Ray Dolby Brain Health Center, Sutter Health/CPMC
San Francisco, CA
Consult Pharmacist Aging and Adult Health Services
San Francisco Health Department
San Francisco, CA
Julio R. Lopez, PharmD, FCSHP
Chief of Pharmacy Service
VA Northern California Health Care System
Adjunct Clinical Professor
College of Pharmacy
Assistant Clinical Professor
School of Pharmacy
University of California, San Francisco
San Francisco, CA Adjunct Professor
Thomas J. Long School of Pharmacy
University of the Pacific
Visiting Associate Professor and Lecturer
Samuel Merritt University
Pamela Mausner, MD
Helen Berlie, Pharm.D. CDE, BCACP
Clinical Assistant Professor, Pharmacy Practice
Wayne State University
Ambulatory Care Specialist - Diabetes
Health Centers Detroit Medical Group
Senior Editorial Advisor
Gerard Hatheway, PharmD, PhD
Belinda M. Danielson, RPh
Christopher M. DeSoto, PharmD
Angie S. Graham, PharmD
Cynthia Chan Huang, PharmD, MBA
Fred Plageman, PharmD
Editorial Advisor and Clinical Practice Consultant for Nurse Practitioners
Meuleman, RN, C, MS
About the Rx Consultant
The Rx Consultant is a monthly publication dedicated to providing health care professionals with the information they need to
educate patients about drugs and manage drug therapy. The reader is responsible for confirming
the information presented here and interpreting it in relation to each patient's specific situation before utilizing the information.
Any hardware that supports Microsoft Windows, Apple Mac OS, iOS, or Android, and meets the software requirements.
Browser that supports TLS 1.1 + and PDF files.
This includes Microsoft Internet Explorer 11, Google Chrome 38, Google Android OS 5.0 Browser, Apple Safari (version 7 for desktop, 5 for mobile), Mozilla Firefox 27, newer versions of these browsers, as well as some earlier versions that may require additional configuration.
Adobe Acrobat Reader is recommended, and is required for some browsers.
Note: TLS 1.1 and 1.2 support is required for browser security. Click here for TLS browser support details.
Required. Broadband recommended. (T1, DSL, Cable, G4 or higher.)